Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Covariance Analysis of Censored Survival Data

1974 • 1,759 citations

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1970 • 1,450 citations

Dose: A critical factor in cancer chemotherapy

1980 • 851 citations

Twenty years of MOPP therapy for Hodgkin's disease.

1986 • 446 citations

Average relative dose intensity and the impact on design of clinical trials.

1987 • 228 citations

Tumor heterogeneity and drug resistance.

1986 • 210 citations

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

1983 • 181 citations

The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.

1983 • 77 citations

Updated clinical experience with MACOP-B.

1987 • 65 citations

Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.

1980 • 62 citations

Major complications and causes of death in patients treated for Hodgkin's disease.

1987 • 60 citations

Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation.

1985 • 49 citations

Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

1985 • 47 citations

High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.

1987 • 44 citations

Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.

1985 • 38 citations

Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association

1982 • 19 citations